Chemistry:Vebreltinib
From HandWiki
Vebreltinib (also known as bozitinib) is a pharmaceutical drug used for the treatment of cancer.[1][2]
Vebreltinib selectively binds to c-Met, preventing its phosphorylation and thereby disrupting c-Met signal transduction pathways.[3]
In China, it is approved for the treatment of non-small-cell lung cancer (NSCLC) with MET exon 14 skipping mutations.[4]
References
- ↑ "Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer". Therapeutic Advances in Medical Oncology 13. 2021. doi:10.1177/1758835921992976. PMID 33643443.
- ↑ "Targeting MET in NSCLC: An Ever-Expanding Territory". JTO Clinical and Research Reports 5 (2). February 2024. doi:10.1016/j.jtocrr.2023.100630. PMID 38361739.
- ↑ "Vebreltinib". NCI Drug Dictionary. U.S. National Institutes of Health. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/vebreltinib.
- ↑ "Vebreltinib Receives Approval in China For MET Exon 14+ NSCLC". November 16, 2023. https://www.onclive.com/view/vebreltinib-receives-approval-in-china-for-met-exon-14-nsclc.
 |  |
